Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM11260C dose-finding study versus placebo and liraglutide in adults with type 2 diabetes mellitus
NL-OMON40381Phase 2Withdrawn
- Sponsor
- Hanmi Pharmaceutical
- Start
- Nov 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efpeglenatide in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change in HbA1c from baseline at Week 13. Planned start Nov 2013; status: withdrawn.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40381.